Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-estab...
UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target f...
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.65) to $(0.35) vs $(0.55) analyst estimate. Raises FY202...
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0....
